Business Standard

Pricing pressure in US market to impact margins of pharma companies

Lack of new launches due to inspection delays, intensifying competition key headwinds

Pharma stocks, firms, earnings
Premium

Representational image

Ram Prasad Sahu
The margins of Indian generic drug makers could be under pressure given rising instance price erosion in the US market. Further, the drop in new launches given the lack of inspection and approvals by the US Food and Drug Administration (USFDA) amid intensifying competition is adding to the margin worries. 

The National Average Drug Acquisition Cost or NADAC data, which captures the price pharmacies in the US pay for medications indicates that 73 per cent of generic drugs during February to March 2021 have seen some degree of price erosion as compared to 47 per cent of drugs in this

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in